Compare CXII & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXII | AVTX |
|---|---|---|
| Founded | 2026 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.4M | 710.1M |
| IPO Year | 2026 | 2015 |
| Metric | CXII | AVTX |
|---|---|---|
| Price | $10.49 | $7.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 27.3K | ★ 3.0M |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $10.05 | $6.53 |
| 52 Week High | $10.99 | $24.27 |
| Indicator | CXII | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 36.53 |
| Support Level | $10.34 | $6.53 |
| Resistance Level | $10.45 | $20.54 |
| Average True Range (ATR) | 0.03 | 0.64 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 41.18 | 44.51 |
Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.